← Back to Search

Tyrosine Kinase Inhibitor

Dacomitinib for Lung Cancer

Q: What indications are traditionally addressed with Dacomitinib?

Dacomitinib is an effective treatment for patients with point mutation in exon 21 (l858r), EGFR exon 19 deletion mutations, and non-small cell lung carcinoma (<a href="https://www.withpower.com/clinical-trials/nsclc">NSCLC</a>).

Q: Does this trial represent a pioneering approach to research?

AstraZeneca sponsored the inception of Dacomitinib research in 2013, and supported its successful transition to Phase 1 &#x26; 2 approval following a 603-participant study. Currently, there are 108 running studies for this drug across 1062 cities and 51 countries worldwide.

Q: How many medical settings are conducting this research trial?

Eleven different medical centres are recruiting patients for this study, including Memoral Sloan Kettering Monmouth in Middletown, Memoral Sloan Kettering Westchester in Harrison and Memorial Sloan Kettering Rockville Centre in Rockville Centre. Additionally, 8 other locations across the US offer participation opportunities.

Q: Are there any existing studies exploring the efficacy of Dacomitinib?

Dacomitinib originated in 2013 at Research Site, with a total of 62 studies now completed. Currently, 108 trials are actively enrolling patients; many of these sites can be found near Middletown, <a href="https://www.withpower.com/clinical-trials/new-york">New york</a>.

Q: How many participants are being recruited for this research?

This research project is no longer accepting enrolment. It was initially listed on the 21st of November 2018 and last updated two years later. If you are searching for other trials, there are currently 1663 studies seeking patients with EGFR gene mutations as well as 108 clinical tests recruiting participants to receive Dacomitinib treatments.

Q: Has recruitment for this research program commenced?

As per information on clinicaltrials.gov, this trial is not currently open for recruitment. The medical experiment was first posted in November 2018 and edited two years later but there are still 1771 other trials actively searching for volunteers at present.

Phase < 1

Waitlist Available

Led By Helen Yu, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial will test whether dacomitinib is effective in treating lung cancer that has progressed despite treatment with osimertinib.

Eligible Conditions

Lung Cancer
Epidermal Growth Factor Receptor Mutations

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Response Rate

Secondary outcome measures

Overall survival

Progression-free survival

Trial Design

2Treatment groups

Experimental Treatment

Group I: Cohort 2: Participants treated with dacomitinib in combination with osimertinibExperimental Treatment2 Interventions

Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation

Group II: Cohort 1: Participants treated with dacomitinib aloneExperimental Treatment1 Intervention

Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Dacomitinib

FDA approved

Osimertinib

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,935 Previous Clinical Trials

588,838 Total Patients Enrolled

Helen Yu, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What indications are traditionally addressed with Dacomitinib?

"Dacomitinib is an effective treatment for patients with point mutation in exon 21 (l858r), EGFR exon 19 deletion mutations, and non-small cell lung carcinoma (NSCLC)."

Answered by AI

Does this trial represent a pioneering approach to research?

"AstraZeneca sponsored the inception of Dacomitinib research in 2013, and supported its successful transition to Phase 1 & 2 approval following a 603-participant study. Currently, there are 108 running studies for this drug across 1062 cities and 51 countries worldwide."

Answered by AI

How many medical settings are conducting this research trial?

"Eleven different medical centres are recruiting patients for this study, including Memoral Sloan Kettering Monmouth in Middletown, Memoral Sloan Kettering Westchester in Harrison and Memorial Sloan Kettering Rockville Centre in Rockville Centre. Additionally, 8 other locations across the US offer participation opportunities."

Answered by AI

Are there any existing studies exploring the efficacy of Dacomitinib?

"Dacomitinib originated in 2013 at Research Site, with a total of 62 studies now completed. Currently, 108 trials are actively enrolling patients; many of these sites can be found near Middletown, New york."

Answered by AI

How many participants are being recruited for this research?

"This research project is no longer accepting enrolment. It was initially listed on the 21st of November 2018 and last updated two years later. If you are searching for other trials, there are currently 1663 studies seeking patients with EGFR gene mutations as well as 108 clinical tests recruiting participants to receive Dacomitinib treatments."

Answered by AI

Has recruitment for this research program commenced?

"As per information on clinicaltrials.gov, this trial is not currently open for recruitment. The medical experiment was first posted in November 2018 and edited two years later but there are still 1771 other trials actively searching for volunteers at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

2018. "A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03755102.